Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

Management of Abnormal Pap Smears and Cervical Dysplasia Jennifer L. Ragazzo, M.D. Department of Obstetrics and Gynecology Division of Womens Primary Healthcare.
Update:Pap Smear Guidelines
Cervical Screening Guidelines - for now and the future - Meg McLachlin, MD, FRCPC.
Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.
MANAGEMENT OF ABNORMAL PAP SMEAR
Cervical Screening and HPV testing
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Cervical Cancer American Cancer Society Georgia Department of Human Resources The University of Georgia Cooperative Extension Service.
Updates on Pap Smear Guidelines 2014
Speaker: Decca Mohammed, MD.  Statistics for cervical cancer and HPV  Association of HPV to cervical cancer, and other cancers  Prevention  Screening.
Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.
Cervical Cancer Screening Cristin Colford, MD April 27,2010.
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Spotlight on Cervical Cancer Screening
Cervical Cancer: Prevention and Treatment
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Clinical Uses of HPV DNA Testing
Case Presentations: Pre-Invasive Cervical Neoplasia
Reproductive health. Cancer Definition Cancer Definition The abnormal growth of cells without normal control of body. Types of Cancer  Malignant Cancer.
A Cervical Cancer Decision Model to Inform Recommendations About Preventive Services Perspective of the Decision Modeler Shalini Kulasingam, PhD Duke University.
Cervical Cancer Screening
HPV and Cervical Cancer Screening and Prevention.
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.
Women’s First Health Center Drs. Sylvester, Youngren, Lo and Sansobrino What You Should Know About Cervical Cancer: Part one in a series of four updates.
CURRENT NATIONAL PREVENTIVE HEALTH CARE GUIDELINES Juanita Halls, M.D. Professor of Medicine General Internal Medicine University of Wisconsin - UW Health.
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Cervical Cancer Screening Recommendations 2012, FDA Panel 2014.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Screening for Cervical Cancer Dr. Shanthi Manivannan, MD.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
Current guidelines for Cervical Cancer Screening
Hot Topics Clinical Medicine ACHA Annual Meeting Boston, MA May 31, 2013.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
Cervical Intraepithelial Neoplasm
Top Pap smear Questions. 1-When should Pap screening begin? Age 21 y/o,3yrs after first intercourse.
Board Review Clinical Epi and Prevention Cristin Colford, MD June 15 th, 2008.
Cervical Cancer Screening Guidelines Update
Cytologic Findings in Type 2 Cervical Carcinomas: Some Cervical Carcinomas are more Difficult to Prevent with Screening R. Marshall Austin MD,PhD Magee-Womens.
Premalignant lesions of the cervix. Applied anatomy.
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
What is a Pap smear? is a medical procedure in which a sample of cells from a woman's cervix is collected and spread (smeared) on a microscope slide.
COLPOSCOPY QUESTIONS Michael R. Downs M.D. October 2004.
Decoding the USPSTF By: Dr Vikram Arora Heritage Valley Health System.
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
To pap or not to pap: and what to do when you do Kimberly Swan MD Minimally Invasive Gynecologic Surgery Assistant Professor Ob/Gyn University of Kansas.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cervical Cancer Screening With Both Human Papillomavirus.
HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.
Cytopathology Feb
Morphologic Pap Test Findings in HPV Negative Women Age 30 Years and Older: What Information Will Be Lost with HPV Only Primary Screening? Brooke Henninger,
1 Cervical Cancer Screening Updates Dr. GORDON JOHNSON.
Cervical Cancer Screening
Cervical Cancer in California
Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.
Updates on Pap Smear Guidelines 2014
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
Cervical Screening for Dysplasia and Cancer in Patients with HIV
What is a Pap smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the uterus that.
SH-sheikhhasani Gyn-oncologist
American Society of Cytopathology’s CELL Talks
Presentation transcript:

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening for Cervical Cancer Management of the Abnormal Pap smear DOC Clinic report Author: Amy Shaheen, MD Assistant Professor of Clinical Medicine Duke University Medical Center

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum How often should Pap smears be done? The American Cancer Society and ACOG both recommend that initial testing should be performed annually, then screening interval can be increased to every 2-3 in women with 3 or more consecutive normal results who are 30 years and older. (ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August Cervical cytology screening. Obstet Gynecol 2003 Aug;102(2): ) The USPSTF recommends the screening interval can be 2-3 years in all women of any age who have had at least 2 normal annual pap smears.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum At what age do I begin screening? Opinions vary on age at which the first pap should be done. ACOG recommends screening by 3 years after onset of sexual activity, or at age 21, whichever comes first. (previously recommended age 18). USPSTF recommends within 3 yrs of onset of sexual activity or age 21. Hysterectomy for benign disease: The USPSTF recommends against screening. They state that yield of cytologic testing is low, and there is poor evidence to suggest screening for vaginal cancer improves outcomes. The ACOG also states such women may discontinue testing.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Begin Screening (2) High-risk patients: Patients with previous cervical cancer, HIV, immunosuppression, or DES exposure while in utero. –Most guidelines simply suggest more frequent screening. –ACOG states regarding women with previous CIN: “Women who have had such a hysterectomy but who have a history of abnormal cell growth (classified as CIN 2 or 3) should be screened annually until they have three consecutive, negative vaginal cytology tests; then they can discontinue routine screening.”

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum At what age do I stop screening? “The USPSTF recommends against routinely screening women older than age 65 if they have had adequate recent screening with normal Pap smears and are not at otherwise high risk for cervical cancer.” ACS calls for cessation of testing in non-high-risk women at age 70. ACOG does not set an upper age limit due to limited studies of older women.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum What do I do with abnormal results? Guidelines that follow are taken from 2001 Consensus guidelines for the management of women with cervical cytological abnormalities, JAMA (16): To devise these guidelines, a panel of 121 experts in the diagnosis and management of cervical cancer precursors were assembled. They were invited to participate in a consensus conference, and developed the guidelines after a formal review of the literature, and obtaining input from the professional community through internet bulletin boards.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum What do I do with abnormal results? (2) Unsatisfactory- repeat in 2-4 months; if test repeatedly unsatisfactory, perform additional evaluation with colposcopy/ biopsy as appropriate. One study showed that women with unsatisfactory Paps are more likely to have cancer on follow-up that those with satisfactory Paps. (Ransdell JS et al. Cancer 1997 Jun 25;81(3):139-43) Endocervical cells not present- Opinion varies, but testing can probably safely be performed again in 12 months. Repeat testing in 6 months should be done if previous pap with ASCUS, neoplasia or unexplained glandular abnormality, HPV + for high-risk type in past 12 months, immunosuppression, poor visualization or sampling of the endocervical canal, or insufficient frequency of previous screening.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum What do I do with abnormal results? (3) Blood/ inflammation present- if obscuring of the results and one of the above high-risk concerns, repeat in 6 months.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum What do I do with abnormal results? (4) Intraepithelial/ other cellular abnormalities –ASC-US (Atypical squamous cells of undetermined significance) – repeat cervical cytologic testing, colposcopy, or DNA testing for high-risk types of HPV are all acceptable methods for managing women with ASC-US. Women who test positive for HPV DNA should be referred for colposcopy. Women who test negative may receive cytologic screening again in 12 months. If repeat cytologic screening is the desired option, then interval should be 4-6 months until 2 consecutive negative results are obtained. [see chart below for special circumstances: pregnant, postmenopausal and immunosuppressed women] Rationale: risk of invasive cervical cancer in women with ASC-US is extremely low ( %) The finding of ASC is poorly reproducible among even expert cytologists.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum What do I do with abnormal results? (5) oASC-H (atypical squamous cells, cannot exclude HSIL) - refer for immediate colposcopic evaluation oAtypical glandular cells – “Colposcopy with endocervical sampling is recommended for women with all subcategories of AGC, with the exception that women with atypical endometrial cells should initially be evaluated with endometrial sampling. Endometrial sampling should be performed in conjunction with colposcopy in women older than 35 years with AGC and in younger women with AGC who have unexplained vaginal bleeding. Colposcopy with endocervical sampling is also recommended for women with AIS [Adenocarcinoma in situ]”

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum What do I do with abnormal results? (6) oLSIL (low-grade squamous intraepithelial lesion) – the majority of women with this result have either no cervical lesion, or CIN-1 which often spontaneously regresses. For this reason, women have often just been followed with serial cytology evaluations, however, the 2001 consensus panel recommends referral for colposcopy. Exceptions include postmenopausal women, pregnant women, and adolescents. (please see JAMA article for details) oHSIL (high-grade intraepithelial lesion) – refer for colposcopy and endocervical assessment.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Review questions A 35 y.o. woman comes into your office to discuss family planning. She has been in a monogamous relationship with her current partner for 9 years, and they have both been tested for HIV infection and are negative. She hopes to become pregnant and plans to discontinue using condoms. Her most recent Pap test was 1 year ago and was normal. She has had annual pap tests for the past 15 years that have all been normal. (go to the next slide to continue)

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum The correct answer is in 2 years. She can be safely screened at an interval of 3 years, but had her last Pap 1 year ago, so 2 years is correct.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Review questions (continued) An asymptomatic 48 y.o. woman undergoes her annual physical exam. She had a vaginal hysterectomy for uterine leiomyoma 4 years ago. She has had vaginal pap smears every 3 years, all of which have been normal. (go to the next slide to continue)

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum The correct answer is to discontinue pelvic exams and Pap smears. There is no evidence that pelvic exams detect ovarian cancer

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Click here to look at a table that summarizes the management of an abnormal Pap smearClick here to look at a table that summarizes the management of an abnormal Pap smear Please complete the course evaluation here.course evaluation here.

Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum References Wright et al Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA (16): Berg et al. “Screening for Cervical Cancer: Recommendations and Rationale”. U.S. Preventive Services Task Force. Jan ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August Cervical cytology screening. Obstet Gynecol 2003 Aug;102(2): UpToDate Online 12.2 “Management of the abnormal Papanicolaou smear.” Ransdell JS et al. Cancer 1997 Jun 25;81(3):